TrialDiabetes, obesity & metabolism2023

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.

Peter Rossing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.